Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with ...

AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced milestones in the expected timeline for the ...

MoonLake Immunotherapeutics has kicked off a year of readouts for its much-hyped inflammatory disease prospect with a ...

Dare´ Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science ...

AstraZeneca is taking its oral GLP-1 drug into phase 3 on the back of a pair of midstage weight loss wins, despite remaining ...

–Remain On Track to Initiate CYC-126's Phase 2 Proof-of-Concept (“POC”) Study in Treatment Resistant Depression (“TRD”) in the Second Half of 2026– ...

NovaBridge Biosciences said it enrolled its first patient in a Phase 2 study evaluating a treatment for certain patients with gastric cancer. The biotechnology company said Tuesday it expects top-line ...

The MARITIME Phase 3 Chronic Weight Management Studies are Actively Enrolling, and Phase 3 Studies in People Living With Atherosclerotic Cardiovascular Disease, Heart Failure and Obstructive Sleep ...

Connect Biopharma Holdings Limited has announced the initiation of its Phase 2 Seabreeze STAT Asthma study, which aims to evaluate the safety and efficacy of rademikibart in treating acute ...

– Alixorexton is the First Oral Orexin 2 Receptor Agonist to Demonstrate Efficacy in a Large Phase 2 Study in Patients With Narcolepsy Type 2, Supporting Advancement to Phase 3 – – Alixorexton Met the ...

Seres said the pause follows the completion of study site evaluation and qualification work with its contract research organization. ・The company said following the pause in additional investment into ...

SAN DIEGO, Dec. 9, 2025 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced that they will ...